Lurbinectedin, also known as Zepzelca, is a medication used to treat small cell lung cancer (SCLC) [2]. According to Drugs.com, the average retail price for a 4mg vial of Lurbinectedin is around $3,840 [3]. However, the actual cost of Lurbinectedin may vary depending on various factors such as insurance coverage, dosage, and treatment duration.

A study published in Targeted Oncology found that Lurbinectedin is a cost-effective second-line treatment option for SCLC patients [2]. The study analyzed the cost-effectiveness of Lurbinectedin compared to topotecan, another second-line treatment for SCLC. The study found that the cost per quality-adjusted life year (QALY) gained with Lurbinectedin was $72,889, which is below the commonly accepted threshold of $100,000 per QALY gained.

DrugPatentWatch provides information on the patent status of Lurbinectedin, but does not provide information on its cost [1].

In conclusion, the average retail price of Lurbinectedin is around $3,840 per 4mg vial [3]. However, the actual cost may vary depending on various factors such as insurance coverage, dosage, and treatment duration. A study published in Targeted Oncology found that Lurbinectedin is a cost-effective second-line treatment option for SCLC patients [2].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.targetedonc.com/view/lurbinectedin-is-cost-effective-as-a-second-line-treatment-in-sclc
[3] https://www.drugs.com/price-guide/zepzelca